Acrivon Therapeutics company info

What does Acrivon Therapeutics do?
Acrivon Therapeutics (NASDAQ:ACRV) is a pioneering force in the realm of precision oncology, focusing on the development of advanced treatments tailored to combat cancer more effectively. The company zeroes in on unlocking personalized therapy options by leveraging its proprietary platform to predict patient responses to its investigational drugs. This approach not only aims to enhance the success rates of cancer treatments but also seeks to significantly improve patient outcomes by aligning therapies with individual genetic profiles. Acrivon Therapeutics is dedicated to pushing the boundaries of medical science, with ongoing projects aimed at addressing various forms of cancer. Its objectives encompass advancing its pipeline of targeted therapies through clinical trials, with the ultimate goal of achieving regulatory approval and bringing novel, effective cancer treatments to the market.
Acrivon Therapeutics  company media
Company Snapshot

Is Acrivon Therapeutics a public or private company?

key
Ownership
Public

How many people does Acrivon Therapeutics employ?

people
Employees
65

What sector is Acrivon Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Acrivon Therapeutics ?

location pin
Head Office
Watertown, United States

What year was Acrivon Therapeutics founded?

founded flag
Year Founded
2018
What does Acrivon Therapeutics specialise in?
/Biopharmaceutical Industry /Cancer Treatment /Immuno-oncology Therapies /Research and Development /Patent Protected /Medical Innovation

What are the products and/or services of Acrivon Therapeutics ?

Overview of Acrivon Therapeutics offerings
Development of precision oncology medicines utilizing proprietary Predictive Precision Proteomics platform to match patients with effective treatments.
Advancement of ACR-368, a targeted therapy aimed at specific cancer mutations, into clinical trials.
Collaboration on biomarker discovery projects to enhance personalization in cancer treatment, leveraging advanced proteomics and computational technologies.
Provision of comprehensive molecular diagnostic services to identify actionable mutations in cancer patients.
Research on novel drug targets for hard-to-treat cancers, based on in-depth tumor biology understanding.
Partnership programs with pharmaceutical companies to co-develop targeted therapies for various cancer types.

Who is in the executive team of Acrivon Therapeutics ?

Acrivon Therapeutics leadership team
  • Dr. Peter  Blume-Jensen M.D., Ph.D.
    Dr. Peter Blume-Jensen M.D., Ph.D.
    Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
  • Ms. Kristina  Masson M.B.A., Ph.D.
    Ms. Kristina Masson M.B.A., Ph.D.
    Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director
  • Mr. Rasmus  Holm-Jorgensen
    Mr. Rasmus Holm-Jorgensen
    Chief Financial Officer
  • Dr. Eric J. Devroe Ph.D.
    Dr. Eric J. Devroe Ph.D.
    Chief Operating Officer
  • Ms. Katharine  Peterson CPA
    Ms. Katharine Peterson CPA
    Vice President of Finance & Accounting
  • Dr. Adam D. Levy M.B.A., Ph.D.
    Dr. Adam D. Levy M.B.A., Ph.D.
    Senior VP and Head of Investor Relations & Corporate Affairs
  • Mr. Bruce  Close
    Mr. Bruce Close
    Vice President of Quality & Compliance
  • Ms. Mary-Alice  Miller J.D.
    Ms. Mary-Alice Miller J.D.
    Chief Legal Officer